MDA-9/Syntenin small molecule inhibitor IVMT-Rx-4 blocks prostate cancer bone metastasis - PubMed
6 hours ago
- #bone metastasis
- #prostate cancer
- #MDA-9/Syntenin
- Bone metastasis is a common and incurable outcome of advanced prostate cancer (PC).
- MDA-9/Syntenin, a pro-metastatic gene, plays a key role in interactions between tumor cells and bone marrow-derived mesenchymal stromal cells (BM-MSCs).
- IVMT-Rx-4, a small molecule inhibitor, shows promise in blocking prostate cancer bone metastasis by targeting MDA-9/Syntenin interactions.
- IVMT-Rx-4 has improved druggable properties, such as higher solubility and lower efflux, compared to its precursor PDZ1i.
- The inhibitor works by suppressing tumor-derived PDGF-AA and related signaling in BM-MSCs, leading to anti-invasive and anti-metastatic effects.
- Combining IVMT-Rx-4 with docetaxel enhances survival in experimental bone metastasis models.
- The study suggests IVMT-Rx-4 could complement standard treatments and improve outcomes for advanced PC patients.
- The research provides a foundation for translational strategies to address complications from advanced prostate cancer.